Literature DB >> 23785204

Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.

Hongquan Wan1, Jin Gao, Kemin Xu, Hongjun Chen, Laura K Couzens, Katie H Rivers, Judy D Easterbrook, Kevin Yang, Lei Zhong, Mohsen Rajabi, Jianqiang Ye, Ishrat Sultana, Xiu-Feng Wan, Xiufan Liu, Daniel R Perez, Jeffery K Taubenberger, Maryna C Eichelberger.   

Abstract

Influenza A viruses, including H1N1 and H5N1 subtypes, pose a serious threat to public health. Neuraminidase (NA)-related immunity contributes to protection against influenza virus infection. Antibodies to the N1 subtype provide protection against homologous and heterologous H1N1 as well as H5N1 virus challenge. Since neither the strain-specific nor conserved epitopes of N1 have been identified, we generated a panel of mouse monoclonal antibodies (MAbs) that exhibit different reactivity spectra with H1N1 and H5N1 viruses and used these MAbs to map N1 antigenic domains. We identified 12 amino acids essential for MAb binding to the NA of a recent seasonal H1N1 virus, A/Brisbane/59/2007. Of these, residues 248, 249, 250, 341, and 343 are recognized by strain-specific group A MAbs, while residues 273, 338, and 339 are within conserved epitope(s), which allows cross-reactive group B MAbs to bind the NAs of seasonal H1N1 and the 1918 and 2009 pandemic (09pdm) H1N1 as well as H5N1 viruses. A single dose of group B MAbs administered prophylactically fully protected mice against lethal challenge with seasonal and 09pdm H1N1 viruses and resulted in significant protection against the highly pathogenic wild-type H5N1 virus. Another three N1 residues (at positions 396, 397, and 456) are essential for binding of cross-reactive group E MAbs, which differ from group B MAbs in that they do not bind 09pdm H1N1 viruses. The identification of conserved N1 epitopes reveals the molecular basis for NA-mediated immunity between H1N1 and H5N1 viruses and demonstrates the potential for developing broadly protective NA-specific antibody treatments for influenza.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23785204      PMCID: PMC3754050          DOI: 10.1128/JVI.01203-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).

Authors:  Upma Gulati; Chi-Ching Hwang; Lalitha Venkatramani; Shelly Gulati; Stephen J Stray; Janis T Lee; W Graeme Laver; Alexey Bochkarev; Adam Zlotnick; Gillian M Air
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.

Authors:  P Palese; K Tobita; M Ueda; R W Compans
Journal:  Virology       Date:  1974-10       Impact factor: 3.616

4.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

5.  Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.

Authors:  Mikhail N Matrosovich; Tatyana Y Matrosovich; Thomas Gray; Noel A Roberts; Hans-Dieter Klenk
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

7.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

8.  Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.

Authors:  P L Ogra; T Chow; K R Beutner; E Rubi; J Strussenberg; S DeMello; C Rizzone
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

9.  The antigenic relationship of the neuraminidase of Hong Kong virus to that of other human strains of influenza A virus.

Authors:  J L Schulman; E D Kilbourne
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

10.  Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies.

Authors:  W Gerhard; R G Webster
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

View more
  76 in total

1.  Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Authors:  Matthew J Memoli; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Kathleen Proudfoot; Sarah Fargis; Matthew Stein; Rebecca L Dunfee; Pamela A Shaw; Richard T Davey; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

Review 2.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

5.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

6.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

7.  A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.

Authors:  Alison Han; Lindsay M Czajkowski; Amanda Donaldson; Holly Ann Baus; Susan M Reed; Rani S Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

8.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

9.  Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.

Authors:  Hongquan Wan; Li Qi; Jin Gao; Laura K Couzens; Lianlian Jiang; Yamei Gao; Zong-Mei Sheng; Sharon Fong; Megan Hahn; Surender Khurana; Jeffery K Taubenberger; Maryna C Eichelberger
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

10.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.